The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
News|Articles|June 16, 2016
OMCL Network Met Market Demand in Europe During 2015
Author(s)Pharmaceutical Technology Editors
The OMCL Network met increasing market demand for testing quality of medicinal products, blood-derived medicinal products, and vaccines in Europe.
Advertisement
During the General European Official Medicines Control Laboratories (OMCL) Network annual meeting, from May 28â29, 2016, the network revealed how it worked to meet increasing market demand for independently testing the quality of medicines, blood-derived medicinal products, and vaccines in Europe.
In a June 15, 2016
, the OMCL said that in 2015, the laboratory dealt with a combined 12,000 final lots proposed for the Official Control Authority Batch Release (OCABR) Network for human-blood derived products and vaccines. Additionally, in 2015 the Official Control Authority Batch Release (OCABR) Network carried out 12% more protocol reviews and testing of final lots of blood-derived medicinal products under the OCABR system compared with the previous year.
Representatives from 61 OMCLs in 38 countries said that more than 1000 product-testing projects were added to the OMCL Network’s 2015 work program for the market surveillance of medicinal products authorized in the European Economic area via the Mutual Recognition Procedure (MRP) and Decentralized Procedure System (DCP). The 996 test reports entered into the OMCL database in 2015, represents a 23% increase compared with 2013.
The majority of the MRP/DCP products tested in 2015 were generic drugs, the network said in a press announcement. According to OMCL, approximately 55% of all dispensed medicines in Europe are generic drugs. The savings relative to branded products are estimated to be around 20% in the first year of generic entry in the market, rising to 25% after two years, the network wrote.
Source:
Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5